The Capital Network

  • Home
  • The Capital Network

The Capital Network Empowering extraordinary entrepreneurs, innovators and investors 🌏 Australia's premier boutique investor, media and digital relations agency

The Capital Network (TCN) is Australia's premier boutique investor, media and digital relations agency, supported by a team of experienced financial markets professionals. Our mission is to empower extraordinary entrepreneurs, innovators and investors through providing ethical and best practice advisory. The strength of our expanding network of business media and investors enables us to generate t

ailored and powerful outcomes and international investor access. Our successful track record has enabled thousands of investors and emerging companies to achieve their professional objectives through The Capital Network. Learn more: www.thecapitalnetwork.com.au
Get in touch: [email protected]

31/01/2025

AdAlta Ltd (ASX:1AD) has released its quarterly, with highlights including:

- Expanded advisor network engaged to support “East to West” cellular therapy strategy
- First non-binding term sheet executed for “East to West” cellular therapy strategy
- AD-214 partnering to be supported by new advisors, stronger ex*****on capabilities and new data from continuous manufacturing improvement program
- New AdAlta Board members appointed, strategic review nearing completion

“The signing of our first non-binding term sheet to in-license an asset as part of our “East to West” cell therapy strategy was a crucial step in building this exciting business. We are now focussing on securing additional term sheets to build our pipeline. We continue positive discussions about AD-214 with a number of new and continuing parties and are encouraged by the recent licensing of Mediar Therapeutic’s IPF candidate by Eli Lilly. Data generated during the December quarter will further support partnering discussions for this important drug candidate." - Tim Oldham, AdAlta CEO & Managing Director

ASX announcement: https://lnkd.in/gPWTZrP5

31/01/2025

Optiscan Imaging Ltd (ASX:OIL) has released its quarterly, with highlights including:

- The signing of a Collaborative Research Agreement with the University of Minnesota College of Veterinary Medicine
- Commencement of the development of a dedicated veterinary imaging product
- The signing of an agreement with Monash University to develop AI technology solutions for gastroenterology imaging
- The completion of key CRC-P grant milestones, securing additional $0.398m of funding.

“Optiscan enjoyed a highly successful December 2024 quarter, as it continued to advance its core priorities that cut across R&D, commercialization, and market expansion, headlined by the achievement of multiple milestones that position the Company for sustained growth. Key highlights over the quarter were delivery of our first flexible GI scope prototype to University Medical Centre of the Johannes Gutenberg University Mainz for evaluation and the signing of a Collaborative Research Agreement with the University of Minnesota College of Veterinary Medicine for veterinary imaging applications." - Dr Camile Farah, Optiscan CEO & Managing Director

ASX announcement: https://lnkd.in/gvmiKTs8

30/01/2025

Veris (ASX: VRS) has executed a Share Sale Agreement to acquire 100% of Spatial Vision Innovations Pty Ltd, for an enterprise value of up to $3.0 million and highlights:

- The acquisition will significantly bolster and strengthen Veris’ existing digital solutions and advisory service offering
- Spatial Vision is expected to generate over $9m of revenue on an annualised basis. Veris expects the acquisition to be accretive to Veris’ performance from FY26
- The acquisition expands Veris’ reach to key clients across Local, State and Federal Government agencies
- Spatial Vision operations are strongly aligned to Veris’ continued pivot towards the digital transformation needs of industry and government sectors
- Spatial Vision’s skillset and strength of relationships in key local, State and Federal Government sectors that complement Veris’ national presence and key client focus

"We are thrilled to welcome the Spatial Vision team into the Veris family. This acquisition is a strategic step forward in our strategy to provide unparalleled digital solutions, consulting and advisory services. By integrating Spatial Vision’s spatial and GIS capabilities with our existing expertise and skillsets we are set to deliver even greater value to our clients and drive innovation in the delivery of spatial data-based digital solutions. Together, we will create a powerhouse of innovative digital solutions, ready to meet the evolving needs of our clients”. - Michael Shirley, Veris CEO & Managing Director

ASX announcement: https://lnkd.in/d36xgkAG

30/01/2025

Nickel Industries (ASX:NIC) is pleased to release its latest quarterly report and an update on its recently acquired Sampala Project. Highlights for the quarter and the Sampala Project include:

🔹Achieves US$72.4 million in operating earnings (EBITDA) in the December quarter from its portfolio of mining and processing operations in Indonesia
🔹Defines an Exploration Target at Sampala of between 350 and 700 million dry metric tonnes (dmt) at 0.9% to 1.1% nickel, adding to the existing 187 million dmt resource base at the project
🔹Commences mine development and main haul road construction at Sampala

ASX announcement: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02907115-2A1575384
Quarterly announcement: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02907197-2A1575408

30/01/2025

Nickel Industries Limited (ASX:NIC) is pleased to release our quarterly, with highlights including:

- US$72M EBITDA from Operations (underlying EBITDA of approx. US$92M)
- Record quarterly HNC EBITDA of US$14.7M
- Record 7,194,202 wmt of nickel ore produced at the Hengjaya Mine
- ENC progressing well, all three autoclaves now on site
- Impressive Sampala Project exploration target of 350m to 700m dmt, in addition to existing 187m dmt resource

“We are pleased to report another strong quarter with a number of new records again set including a record quarterly contribution of US $14.7 million from our 10% interest in the HNC HPAL, which bodes very well for our ENC HPAL where construction progress is on track to deliver first production in the second half of 2025." - Justin Werner, Nickel Industries Managing Director

ASX announcement:https://announcements.asx.com.au/asxpdf/20250130/pdf/06dz4jj4pd5zdd.pdf

To arrange a meeting with management, please contact: [email protected]

30/01/2025

OncoSil Medical (ASX:OSL) is pleased to release our quarterly, with highlights including:

- The signing of distribution agreements for GCC, Egypt and Nordics
- The receipt of UKCA Renewal Certificates
- G-BA clinical trial approval received for OncoSil Device
- First OncoSil Treatment at Instituto Nazionale dei Tumori, Milan, Italy
- First patient in Australia Randomised in TRIPP-FFX Trial

“This has been an exceptional quarter for OncoSil Medical, marked by significant progress across multiple fronts. Each of these achievements strengthens our position as a leader in this field and demonstrates our commitment to improving outcomes for patients worldwide.” - Nigel Lange, OncoSil Medical CEO & Managing Director

ASX announcement:https://announcements.asx.com.au/asxpdf/20250130/pdf/06dyx5fhw1xb7k.pdf

To arrange a meeting with management, please contact: [email protected]

28/01/2025

OncoSil Medical (ASX:OSL) has received Medical Device Regulation (MDR) certification from BSI, the EU Notified Body. The certification includes the lifting of existing post-market restrictions. This milestone highlights the growing robust clinical evidence supporting the safety of the OncoSil™ device and marks a significant step forward for the company | ASX announcement:https://announcements.asx.com.au/asxpdf/20250128/pdf/06dwhydjbzflp2.pdf

28/01/2025

Veris (ASX:VRS) has announced an unaudited trading update for the six months ended 31 December 2024 with further improvement in financial performance delivered, as digital strategy ex*****on & FY24 restructuring initiatives gain traction and highlights:

- Veris’ cash balance of $17.6m at 31 December 2024 reflected a strong increase from $16.1m at 30 June 2024
- The improvement seen in Veris’ H1 FY25 financials reflects the successful ex*****on of the Company’s transformation strategy
- The order book remained strong, with a secured forward workload in excess of $55 million as at end-H1 FY25.
- Unsecured project pipeline remains steady with a weighted value of more than $190 million

"Looking ahead, we are confident that our continued commitment to key strategic priorities will further enhance our financial performance and solidify our position as a leader in digital and spatial data advisory and consulting services over 2025 and beyond.” - Michael Shirley CEO & Managing Director

ASX announcement:https://announcements.asx.com.au/asxpdf/20250128/pdf/06dw1stv1wtbs2.pdf

15/01/2025

Pancreatic cancer treatment device company OncoSil Medical (ASX:OSL) is pleased to announce the appointment of Ms. Lel Smits as a Non-Executive Director to the Board of OncoSil Medical, effective immediately.

"We are delighted to welcome Lel to the OncoSil Board. Her extensive experience across governance, strategy, and corporate affairs will be invaluable as we continue to advance our mission of delivering innovative treatments to patients globally. Her strategic insights and leadership in investor relations will undoubtedly strengthen our efforts to create value for all stakeholders." - Nigel Lange, CEO & Managing Director of OncoSil Medical

“I am honoured to join the Board of OncoSil Medical at such a pivotal time for the company. OncoSil’s commitment to improving patient outcomes aligns with my passion for fostering innovation and governance excellence. I look forward to utilising my extensive experience across corporate communications, media and investor relations to contribute to the company’s strategic objectives and supporting its growth journey” - Lel Smits

ASX announcement:https://announcements.asx.com.au/asxpdf/20250115/pdf/06dk3w2j1hltvs.pdf

Echelon (ASX:ECH) has executed a binding Terms Sheet with London Stock Exchange listed energy company, Mosman Oil & Gas,...
15/01/2025

Echelon (ASX:ECH) has executed a binding Terms Sheet with London Stock Exchange listed energy company, Mosman Oil & Gas, to purchase the 100% interest in the Northern Territory onshore Exploration Permit EP145, in the Amadeus Basin and highlights:

- Purchase price of AUD400,000 cash payment
- 5 per cent royalty on Helium and Hydrogen
- Agreement subject to conditions, including FIRB and regulatory approval

ASX announcement: https://lnkd.in/gU7shfgb

Cleo Diagnostics (ASX:COV) has expanded the clinical trial sites for its simple and accurate blood test used in the earl...
11/12/2024

Cleo Diagnostics (ASX:COV) has expanded the clinical trial sites for its simple and accurate blood test used in the early detection of ovarian cancer after adding a network of 13 Victorian clinics operated by prominent women’s ultrasound specialist, Siles Health.

The collaboration with Siles Health seeks to generate key insights into clinical workflows which could ultimately support clinical implementation strategies for successful market adoption of the blood test.

In addition, the partnership supplements Cleo’s broader trial strategy by providing access to a greater cohort of patient samples. In turn, the larger sample size could bolster the company’s planned clinical trial in America where approval from the US Food and Drug Administration (FDA) is required.

Management noted that the cooperation with Siles Health may also boost market awareness and help verify and optimise its diagnostic blood test. It builds on another recent expansion which saw The Royal Women's Hospital in Melbourne join the trial.

Cleo’s primary focus is on the US which is regarded as the world’s largest diagnostic market. Its Australian clinical trial will underpin an FDA submission planned for next year.

Patient recruitment for the US trial remains on track, with samples being collected in line with the trial’s objectives. Here, the company is targeting a minimum of 500 patients who are representative of the American population.

Ovarian cancer is one of the deadliest forms of female reproductive cancers accounting for more than 200,000 fatalities each year. According to Cleo, the current standard of care for the diseases is inadequate with no screening available for its early detection.

Management believes this unmet clinical need creates an opportunity for the company to positively impact women’s lives through accurate and early diagnosis of ovarian cancer with its simple blood test.

Read the full announcementhttps://announcements.asx.com.au/asxpdf/20241210/pdf/06cgbsd89328rt.pdf

04/12/2024

Investors, ASX CEOs and professional services, you are invited to join us for the ultimate business and rugby experience in Hong Kong. Showcase your business to Asia's top institutional investors while soaking in the electric energy of the Hong Kong Sevens in March next year. Foley Durham and The Capital Network are thrilled to invite you to the "Stocks to Try" Investor Summit

📍 Four Seasons Hotel, Hong Kong
📋 26th-27th March 2025
💼 Investor summit and investor meetings
🏉 Alongside legendary Hong Kong Sevens rugby event

FEATURES
• 20 ASX-listed companies featured
• Media reach to ~250,000 investors
• Direct access to top tier Asian investors
• A unique blend of business and sport in a dynamic setting

OUTCOMES
Grow your network
Connect with high-caliber investors
Amplify your company’s visibility to Hong Kong investors
Access to Asian capital and diversify/expand your investor base

GET IN TOUCH
Limited spots available.
Contact us now to confirm your spot.

[email protected]
[email protected]

INOVIQ (ASX:IIQ), a biotechnology business developing diagnostic and therapeutic solutions for cancer, has delivered “ou...
04/12/2024

INOVIQ (ASX:IIQ), a biotechnology business developing diagnostic and therapeutic solutions for cancer, has delivered “outstanding” results for its EXO-OC blood test for ovarian cancer screening, with an independent patient validation of its biomarkers generating more than 94 per cent accuracy.

Management noted that this favourable outcome represents a major advancement in ovarian cancer testing.

According to the company, ovarian cancer is the 8th most prevalent type of cancer in women, with more than 300,000 new cases of the disease diagnosed around the world each year.

As things stand, there are no approved tests for early detection of the condition in asymptomatic and average-risk women, with earlier-stage and more accurate tests also required for screening of high-risk women.

Management added that the EXO-OC test was particularly accurate in identifying early stages of ovarian cancer.

It returned a sensitivity of more than 90 per cent and a specificity of 96 per cent for ‘stage 1’ of the disease, where women have a five-year survival rate of more than 90 per cent. And early detection and accurate diagnosis play a key role in boosting survival rates and reducing progression of the cancer.

INOVIQ now plans to optimise the blood test on a commercial platform in preparation for delivering the test in a clinical laboratory.

Based on research conducted by Acumen Research and Consulting, the global ovarian cancer diagnostics market was valued at US$1.7 billion in 2023. It is projected to grow to nearly US$3 billion by 2032.

Read the full announcement:https://announcements.asx.com.au/asxpdf/20241203/pdf/06c5mr3p58jhnb.pdf

AML3D (ASX:AL3) Managing Director Sean Ebert joins Alan Kohler for an in-depth discussion about the company's 3D printin...
28/11/2024

AML3D (ASX:AL3) Managing Director Sean Ebert joins Alan Kohler for an in-depth discussion about the company's 3D printing operations and highlights:

➡️ $30M capital raise which secured funding to expand US operations and double production capacity.
➡️ Collaborating with major players like the US Navy and Boeing.
➡️ Global expansion targeting the UK and European markets.

Read more: https://www.intelligentinvestor.com.au/investment-news/life-in-3d/154077

27/11/2024

Variscan Mines (ASX:VAR) Chief Executive Officer and Managing Director Stewart Dickson presented to investors in Sydney supported by The Capital Network's investor introductions program. The company is a growth orientated, natural resources company focused on the acquisition, exploration and development of high quality strategic mineral projects.

To learn more please visit: https://www.variscan.com.au/site/content/

Neurotech International (ASX: NTI), a biopharmaceutical development company focused on paediatric neurological disorders...
27/11/2024

Neurotech International (ASX: NTI), a biopharmaceutical development company focused on paediatric neurological disorders, has received orphan drug designation from the US Food and Drug Administration (FDA) for the application of its flagship NTI164 product in children and adults diagnosed with Rett Syndrome.

In essence, the FDA has authority to grant orphan drug designation to biological products aimed at preventing, diagnosing, or treating rare diseases that impact less than 200,000 people in the US.

In turn, the favourable designation from the FDA could benefit Neurotech by generating tax credits for clinical trials, providing exemption from user fees, and potentially arming the company with a seven-year period of market exclusivity following formal approval of the drug.

Rett Syndrome is a rare genetic neurological and developmental disorder occurring almost exclusively in girls. About 350,000 women worldwide are estimated to suffer from the condition, with an incidence rate of one in 10,000 female live births.

According to Neurotech, Rett Syndrome remains difficult to treat under existing standards of care. As such, new methods for treating the disorder - which are safe and effective - are required.

Management noted that Neurotech’s recent pre-clinical trial on NTI164 demonstrated significant clinical effects in patients diagnosed with the condition, coupled with an excellent safety profile extending beyond the 12-week period of the trial.

The company is targeting a global market opportunity of more than US$2 billion per annum in the treatment of Rett Syndrome.

Read the full announcementhttps://announcements.asx.com.au/asxpdf/20241126/pdf/06bvjrqmjhwwys.pdf

Address


Website

Alerts

Be the first to know and let us send you an email when The Capital Network posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Videos

AdAlta Ltd (ASX:1AD) has released its quarterly, with highlights including: - Expanded advisor network engaged to support “East to West” cellular therapy strategy - First non-binding term sheet executed for “East to West” cellular therapy strategy - AD-214 partnering to be supported by new advisors, stronger execution capabilities and new data from continuous manufacturing improvement program - New AdAlta Board members appointed, strategic review nearing completion “The signing of our first non-binding term sheet to in-license an asset as part of our “East to West” cell therapy strategy was a crucial step in building this exciting business. We are now focussing on securing additional term sheets to build our pipeline. We continue positive discussions about AD-214 with a number of new and continuing parties and are encouraged by the recent licensing of Mediar Therapeutic’s IPF candidate by Eli Lilly. Data generated during the December quarter will further support partnering discussions for this important drug candidate." - Tim Oldham, AdAlta CEO & Managing Director ASX announcement: https://lnkd.in/gPWTZrP5

Optiscan Imaging Ltd (ASX:OIL) has released its quarterly, with highlights including: - The signing of a Collaborative Research Agreement with the University of Minnesota College of Veterinary Medicine - Commencement of the development of a dedicated veterinary imaging product - The signing of an agreement with Monash University to develop AI technology solutions for gastroenterology imaging - The completion of key CRC-P grant milestones, securing additional $0.398m of funding. “Optiscan enjoyed a highly successful December 2024 quarter, as it continued to advance its core priorities that cut across R&D, commercialization, and market expansion, headlined by the achievement of multiple milestones that position the Company for sustained growth. Key highlights over the quarter were delivery of our first flexible GI scope prototype to University Medical Centre of the Johannes Gutenberg University Mainz for evaluation and the signing of a Collaborative Research Agreement with the University of Minnesota College of Veterinary Medicine for veterinary imaging applications." - Dr Camile Farah, Optiscan CEO & Managing Director ASX announcement: https://lnkd.in/gvmiKTs8

Veris (ASX: VRS) has executed a Share Sale Agreement to acquire 100% of Spatial Vision Innovations Pty Ltd, for an enterprise value of up to $3.0 million and highlights: - The acquisition will significantly bolster and strengthen Veris’ existing digital solutions and advisory service offering - Spatial Vision is expected to generate over $9m of revenue on an annualised basis. Veris expects the acquisition to be accretive to Veris’ performance from FY26 - The acquisition expands Veris’ reach to key clients across Local, State and Federal Government agencies - Spatial Vision operations are strongly aligned to Veris’ continued pivot towards the digital transformation needs of industry and government sectors - Spatial Vision’s skillset and strength of relationships in key local, State and Federal Government sectors that complement Veris’ national presence and key client focus "We are thrilled to welcome the Spatial Vision team into the Veris family. This acquisition is a strategic step forward in our strategy to provide unparalleled digital solutions, consulting and advisory services. By integrating Spatial Vision’s spatial and GIS capabilities with our existing expertise and skillsets we are set to deliver even greater value to our clients and drive innovation in the delivery of spatial data-based digital solutions. Together, we will create a powerhouse of innovative digital solutions, ready to meet the evolving needs of our clients”. - Michael Shirley, Veris CEO & Managing Director ASX announcement: https://lnkd.in/d36xgkAG

Nickel Industries (ASX:NIC) is pleased to release its latest quarterly report and an update on its recently acquired Sampala Project. Highlights for the quarter and the Sampala Project include: 🔹Achieves US$72.4 million in operating earnings (EBITDA) in the December quarter from its portfolio of mining and processing operations in Indonesia 🔹Defines an Exploration Target at Sampala of between 350 and 700 million dry metric tonnes (dmt) at 0.9% to 1.1% nickel, adding to the existing 187 million dmt resource base at the project 🔹Commences mine development and main haul road construction at Sampala ASX announcement: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02907115-2A1575384 Quarterly announcement: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02907197-2A1575408

Nickel Industries Limited (ASX:NIC) is pleased to release our quarterly, with highlights including: - US$72M EBITDA from Operations (underlying EBITDA of approx. US$92M) - Record quarterly HNC EBITDA of US$14.7M - Record 7,194,202 wmt of nickel ore produced at the Hengjaya Mine - ENC progressing well, all three autoclaves now on site - Impressive Sampala Project exploration target of 350m to 700m dmt, in addition to existing 187m dmt resource “We are pleased to report another strong quarter with a number of new records again set including a record quarterly contribution of US $14.7 million from our 10% interest in the HNC HPAL, which bodes very well for our ENC HPAL where construction progress is on track to deliver first production in the second half of 2025." - Justin Werner, Nickel Industries Managing Director ASX announcement:https://announcements.asx.com.au/asxpdf/20250130/pdf/06dz4jj4pd5zdd.pdf To arrange a meeting with management, please contact: [email protected]

OncoSil Medical (ASX:OSL) is pleased to release our quarterly, with highlights including: - The signing of distribution agreements for GCC, Egypt and Nordics - The receipt of UKCA Renewal Certificates - G-BA clinical trial approval received for OncoSil Device - First OncoSil Treatment at Instituto Nazionale dei Tumori, Milan, Italy - First patient in Australia Randomised in TRIPP-FFX Trial “This has been an exceptional quarter for OncoSil Medical, marked by significant progress across multiple fronts. Each of these achievements strengthens our position as a leader in this field and demonstrates our commitment to improving outcomes for patients worldwide.” - Nigel Lange, OncoSil Medical CEO & Managing Director ASX announcement:https://announcements.asx.com.au/asxpdf/20250130/pdf/06dyx5fhw1xb7k.pdf To arrange a meeting with management, please contact: [email protected]

OncoSil Medical (ASX:OSL) has received Medical Device Regulation (MDR) certification from BSI, the EU Notified Body. The certification includes the lifting of existing post-market restrictions. This milestone highlights the growing robust clinical evidence supporting the safety of the OncoSil™ device and marks a significant step forward for the company | ASX announcement:https://announcements.asx.com.au/asxpdf/20250128/pdf/06dwhydjbzflp2.pdf

Veris (ASX:VRS) has announced an unaudited trading update for the six months ended 31 December 2024 with further improvement in financial performance delivered, as digital strategy execution & FY24 restructuring initiatives gain traction and highlights: - Veris’ cash balance of $17.6m at 31 December 2024 reflected a strong increase from $16.1m at 30 June 2024 - The improvement seen in Veris’ H1 FY25 financials reflects the successful execution of the Company’s transformation strategy - The order book remained strong, with a secured forward workload in excess of $55 million as at end-H1 FY25. - Unsecured project pipeline remains steady with a weighted value of more than $190 million "Looking ahead, we are confident that our continued commitment to key strategic priorities will further enhance our financial performance and solidify our position as a leader in digital and spatial data advisory and consulting services over 2025 and beyond.” - Michael Shirley CEO & Managing Director ASX announcement:https://announcements.asx.com.au/asxpdf/20250128/pdf/06dw1stv1wtbs2.pdf

Pancreatic cancer treatment device company OncoSil Medical (ASX:OSL) is pleased to announce the appointment of Ms. Lel Smits as a Non-Executive Director to the Board of OncoSil Medical, effective immediately. "We are delighted to welcome Lel to the OncoSil Board. Her extensive experience across governance, strategy, and corporate affairs will be invaluable as we continue to advance our mission of delivering innovative treatments to patients globally. Her strategic insights and leadership in investor relations will undoubtedly strengthen our efforts to create value for all stakeholders." - Nigel Lange, CEO & Managing Director of OncoSil Medical “I am honoured to join the Board of OncoSil Medical at such a pivotal time for the company. OncoSil’s commitment to improving patient outcomes aligns with my passion for fostering innovation and governance excellence. I look forward to utilising my extensive experience across corporate communications, media and investor relations to contribute to the company’s strategic objectives and supporting its growth journey” - Lel Smits ASX announcement:https://announcements.asx.com.au/asxpdf/20250115/pdf/06dk3w2j1hltvs.pdf

Investors, ASX CEOs and professional services, you are invited to join us for the ultimate business and rugby experience in Hong Kong. Showcase your business to Asia's top institutional investors while soaking in the electric energy of the Hong Kong Sevens in March next year. Foley Durham and The Capital Network are thrilled to invite you to the "Stocks to Try" Investor Summit 📍 Four Seasons Hotel, Hong Kong 📋 26th-27th March 2025 💼 Investor summit and investor meetings 🏉 Alongside legendary Hong Kong Sevens rugby event FEATURES • 20 ASX-listed companies featured • Media reach to ~250,000 investors • Direct access to top tier Asian investors • A unique blend of business and sport in a dynamic setting OUTCOMES Grow your network Connect with high-caliber investors Amplify your company’s visibility to Hong Kong investors Access to Asian capital and diversify/expand your investor base GET IN TOUCH Limited spots available. Contact us now to confirm your spot. [email protected] [email protected]

Variscan Mines (ASX:VAR) Chief Executive Officer and Managing Director Stewart Dickson presented to investors in Sydney supported by The Capital Network's investor introductions program. The company is a growth orientated, natural resources company focused on the acquisition, exploration and development of high quality strategic mineral projects. To learn more please visit: https://www.variscan.com.au/site/content/

Globe Metals and Mining (ASX:GBE) Chief Executive Officer Paul Smith presented to investors in Sydney supported by The Capital Network's investor introductions program. The company is an African-focused resources company with its Kanyika Niobium Project in Malawi. To learn more please visit: https://www.globemm.com/

Shortcuts

  • Address
  • Alerts
  • Videos
  • Claim ownership or report listing

  • Want your business to be the top-listed Media Company?

Share